Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Thoracic 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1Lung Neoplasms 1Castrate-Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × OGX-011 × Clear all
NCT01630733 2026-04-15

ENSPIRIT

Achieve Life Sciences

Phase 3 Completed
664 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01188187 2016-10-14

SYNERGY

Achieve Life Sciences

Phase 3 Completed
1,022 enrolled
Genitourinary

Prostatic Neoplasms

NCT01083615 2016-10-12

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Achieve Life Sciences

Phase 3 Terminated
14 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT01578655 2016-10-12

AFFINITY

Achieve Life Sciences

Phase 3 Completed
630 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡